Bayer aims for new Xarelto nod in Japan; Purdue recruits first chief commercial officer; Durata med wins FDA clearance;

> Bayer submitted its clot-fighter Xarelto for approval in Japan, to treat deep vein thrombosis and pulmonary embolism. Report

> Purdue Pharma tapped Saeed Motahari, formerly an AbbVie ($ABBV) VP of sales and marketing, to be its first chief commercial officer. Report

> Durata Therapeutics won FDA approval for its new drug to treat serious bacterial skin infections, Dalvance. Report

> The New York-based health communications group Chandler Chicco Companies, part of inVentiv Health, expanded its digital team with three new senior-level hires. Report

> Hungary's Richter agreed to buy a 51% stake in Mediplus, a Curacao-based company that promotes its products in Latin America. Report

And Finally... The use of antidepressants in England has risen faster than ever since the recession there boosted unemployment. Report